Indaptus Therapeutics is trading at $2.78, up 5.70% during the October 19 session, with the gain most consistent with supportive biotech-sector sentiment—not a confirmed direct catalyst.
- The supplied context reports biotech ETF XBI up 2.09%, amid industry M&A activity and anticipation of cancer-vaccine data.
- No fresh company-specific announcement explaining the gain surfaced in available search results; recent company information instead describes a strategic review and discontinued clinical studies.